ZBH - Zimmer Biomet Holdings, Inc.
After hours:
| Previous close | 135.29 |
| Open | 133.51 |
| Bid | 135.97 x 800 |
| Ask | 136.06 x 800 |
| Day's range | 134.22 - 136.35 |
| 52-week range | 100.39 - 149.25 |
| Volume | |
| Avg. volume | 1,373,839 |
| Market cap | 28.535B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | 63.56 |
| EPS (TTM) | 2.14 |
| Earnings date | 31 Jul 2023 - 04 Aug 2023 |
| Forward dividend & yield | 0.96 (0.74%) |
| Ex-dividend date | 23 Jun 2023 |
| 1y target est | 150.16 |
ZacksHere's Why Investors Should Retain ResMed (RMD) Stock for Now
Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
Simply Wall St.Is Now An Opportune Moment To Examine Zimmer Biomet Holdings, Inc. (NYSE:ZBH)?
Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) received a lot of attention from a substantial price movement on the NYSE...
ZacksSyneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes
Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.
ZacksLabCorp (LH) Provides Update on Planned Spinoff of Fortrea
After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.
ZacksHere's Why Investors Should Retain Thermo Fisher (TMO) Stock
Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.
ZacksHere's Why You Should Invest in IDEXX (IDXX) Right Now
Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.
ZacksHere's Why You Should Invest in Edward Lifesciences (EW) Now
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.
ZacksZimmer (ZBH) Down 8.8% Since Last Earnings Report: Can It Rebound?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksDown -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)
Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksHere's Why You Should Retain Integra (IART) Stock Now
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
ZacksZBH vs. RMD: Which Stock Should Value Investors Buy Now?
ZBH vs. RMD: Which Stock Is the Better Value Option?
ZacksHere's Why You Should Retain Tandem Diabetes (TNDM) Now
Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.
ZacksHere's Why Investors Should Hold Encompass Health (EHC) Now
Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.
- Zacks
Here's Why You Should Retain Globus Medical (GMED) Stock Now
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
- Zacks
Here's Why You Should Retain Bruker (BRKR) Stock for Now
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
- Zacks
Boston Scientific (BSX) Gains From Acquisitions, New Launches
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
ZacksAbbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
- Zacks
Here's Why You Should Retain Chemed (CHE) Stock for Now
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
ZacksHere's Why Investors Should Add Zimmer Biomet (ZBH) Now
Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.
- Zacks
Here's Why You Should Retain Insulet (PODD) Stock for Now
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
- Simply Wall St.
The Returns At Zimmer Biomet Holdings (NYSE:ZBH) Aren't Growing
There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
ZacksHere's Why You Should Retain QIAGEN (QGEN) Stock for Now
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
ZacksHere's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
ZacksHere's Why You Should Retain Charles River (CRL) Stock Now
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
- Zacks
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
